H. Sollinger, Mycophenolates in transplantation, Clinical Transplantation, vol.2, issue.5, pp.485-492, 2004.
DOI : 10.1046/j.1600-6143.2003.00321.x

H. Sollinger, MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTS, Transplantation, vol.60, issue.3, pp.225-232, 1995.
DOI : 10.1097/00007890-199508000-00003

A. Allison and E. Eugui, Mycophenolate mofetil and its mechanisms of action, Immunopharmacology, vol.47, issue.2-3, pp.85-118, 2000.
DOI : 10.1016/S0162-3109(00)00188-0

I. Nowak and L. Shaw, Effect of Mycophenolic Acid Glucuronide on Inosine Monophosphate Dehydrogenase Activity, Therapeutic Drug Monitoring, vol.19, issue.3, pp.358-360, 1997.
DOI : 10.1097/00007691-199706000-00018

J. Ransom, Mechanism of Action of Mycophenolate Mofetil, Therapeutic Drug Monitoring, vol.17, issue.6, pp.681-684, 1995.
DOI : 10.1097/00007691-199512000-00023

P. Hager, F. Collart, E. Huberman, and B. Mitchell, Recombinant human inosine monophosphate dehydrogenase type I and type II proteins, Biochemical Pharmacology, vol.49, issue.9, pp.1323-1329, 1995.
DOI : 10.1016/0006-2952(95)00026-V

J. Gu, S. Stegmann, K. Gathy, R. Murray, J. Laliberte et al., Inhibition of T lymphocyte activation in mice heterozygous for loss of the IMPDH II gene, Journal of Clinical Investigation, vol.106, issue.4, pp.599-606, 2000.
DOI : 10.1172/JCI8669

R. Bullingham, A. Nicholls, and B. Kamm, Clinical Pharmacokinetics of Mycophenolate Mofetil, Clinical Pharmacokinetics, vol.34, issue.6, pp.429-455, 1998.
DOI : 10.2165/00003088-199834060-00002

S. Sanquer, M. Breil, C. Baron, D. Dhamane, A. Astier et al., Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil, Clinical Pharmacology & Therapeutics, vol.65, issue.6, pp.640-648, 1999.
DOI : 10.1016/S0009-9236(99)90085-1

L. Weber, M. Shipkova, T. Lamersdorf, P. Niedmann, M. Wiesel et al., Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients, J Am Soc Nephrol, vol.9, pp.1511-1520, 1998.

L. Meur, Y. Buchler, M. Thierry, A. Caillard, S. Villemain et al., Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation, American Journal of Transplantation, vol.82, issue.1, pp.2496-2503, 2007.
DOI : 10.1097/00007691-200412000-00005

T. Van-gelder, H. Silva, J. De-fijter, K. Budde, D. Kuypers et al., Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial, Transplantation, vol.86, issue.8, pp.1043-1051, 2008.
DOI : 10.1097/TP.0b013e318186f98a

J. Grinyo, Y. Vanrenterghem, B. Nashan, F. Vincenti, H. Ekberg et al., Association of four DNA polymorphisms with acute rejection after kidney transplantation, Transplant International, vol.96, issue.9, pp.879-891, 2008.
DOI : 10.1111/j.1432-2277.2008.00679.x

J. Wang, A. Zeevi, S. Webber, D. Girnita, L. Addonizio et al., A novel variant L263F in human inosine 5???-monophosphate dehydrogenase 2 is associated with diminished enzyme activity, Pharmacogenetics and Genomics, vol.17, issue.4, pp.283-290, 2007.
DOI : 10.1097/FPC.0b013e328012b8cf

T. Van-gelder, D. Hesselink, R. Van-hest, R. Mathot, and S. Van, Pharmacogenetics in Immunosuppressive Therapy, Therapeutic Drug Monitoring, vol.26, issue.4, pp.343-346, 2004.
DOI : 10.1097/00007691-200408000-00001

J. Wang, J. Yang, A. Zeevi, S. Webber, D. Girnita et al., IMPDH1 Gene Polymorphisms and Association With Acute Rejection in Renal Transplant Patients, Clinical Pharmacology & Therapeutics, vol.10, issue.5, pp.711-717, 2008.
DOI : 10.1038/sj.clpt.6100347

F. Vannozzi, F. Filipponi, D. Paolo, A. Danesi, R. Urbani et al., An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients, Transplantation Proceedings, vol.36, issue.9, pp.2787-2790, 2004.
DOI : 10.1016/j.transproceed.2004.09.070

S. Sanquer, P. Maison, C. Tomkiewicz, I. Macquin-mavier, C. Legendre et al., Expression of Inosine Monophosphate Dehydrogenase Type I and Type II After Mycophenolate Mofetil Treatment: A 2-year Follow-up in Kidney Transplantation, Clinical Pharmacology & Therapeutics, vol.14, issue.2, pp.328-335, 2008.
DOI : 10.1038/sj.clpt.6100300

S. Bremer, R. Mandla, N. Vethe, I. Rasmussen, H. Rootwelt et al., Expression of IMPDH1 and IMPDH2 After Transplantation and Initiation of Immunosuppression, Transplantation, vol.85, issue.1, pp.55-61, 2008.
DOI : 10.1097/01.tp.0000296854.68123.03

M. Sintchak, M. Fleming, O. Futer, S. Raybuck, S. Chambers et al., Structure and Mechanism of Inosine Monophosphate Dehydrogenase in Complex with the Immunosuppressant Mycophenolic Acid, Cell, vol.85, issue.6, pp.921-930, 1996.
DOI : 10.1016/S0092-8674(00)81275-1

T. Colby, K. Vanderveen, M. Strickler, G. Markham, and B. Goldstein, Crystal structure of human type II inosine monophosphate dehydrogenase: Implications for ligand binding and drug design, Proceedings of the National Academy of Sciences, vol.96, issue.7, pp.3531-3536, 1999.
DOI : 10.1073/pnas.96.7.3531

T. Farazi, J. Leichman, T. Harris, M. Cahoon, and L. Hedstrom, Isolation and Characterization of Mycophenolic Acid-resistant Mutants of Inosine-5'-monophosphate Dehydrogenase, Journal of Biological Chemistry, vol.272, issue.2, pp.961-965, 1997.
DOI : 10.1074/jbc.272.2.961

M. Mohamed, R. Frye, and T. Langaee, ) Genetic Polymorphisms, Genetic Testing, vol.12, issue.4, pp.513-516, 2008.
DOI : 10.1089/gte.2008.0049

F. Sombogaard, R. Van-schaik, R. Mathot, K. Budde, M. Van-der-werf et al., Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism, Pharmacogenetics and Genomics, vol.19, issue.8, pp.626-634, 2009.
DOI : 10.1097/FPC.0b013e32832f5f1b

R. Van-schaik, M. Van-agteren, J. De-fijter, A. Hartmann, J. Schmidt et al., UGT1A9 -275T>A/-2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus-Treated Kidney Transplant Patients, Clinical Pharmacology & Therapeutics, vol.8, issue.3, pp.319-327, 2009.
DOI : 10.1097/00008571-200103000-00008

N. Djebli, N. Picard, J. Rerolle, L. Meur, Y. Marquet et al., Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients, Pharmacogenetics and Genomics, vol.17, issue.5, pp.321-330, 2007.
DOI : 10.1097/FPC.0b013e32801430f8

P. Wallemacq, V. Armstrong, M. Brunet, V. Haufroid, D. Holt et al., Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference, Therapeutic Drug Monitoring, vol.31, issue.2, pp.139-152, 2009.
DOI : 10.1097/FTD.0b013e318198d092

S. Knight and P. Morris, Does the Evidence Support the Use of Mycophenolate Mofetil Therapeutic Drug Monitoring in Clinical Practice? A Systematic Review, Transplantation, vol.85, issue.12, pp.1675-1685, 2008.
DOI : 10.1097/TP.0b013e3181744199

V. Armstrong, M. Shipkova, E. Schutz, L. Weber, B. Tonshoff et al., Monitoring of mycophenolic acid in pediatric renal transplant recipients, Transplantation Proceedings, vol.33, issue.1-2, pp.1040-1043, 2001.
DOI : 10.1016/S0041-1345(00)02322-8

T. Pawinski, M. Durlik, I. Szlaska, A. Urbanowicz, J. Ostrowska et al., The Weight of Pharmacokinetic Parameters for Mycophenolic Acid in Prediction of Rejection Outcome: The Receiver Operating Characteristic Curve Analysis, Transplantation Proceedings, vol.38, issue.1, pp.86-89, 2006.
DOI : 10.1016/j.transproceed.2005.11.084

K. Takahashi, T. Ochiai, K. Uchida, T. Yasumura, M. Ishibashi et al., Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients, RS-61443 Investigation Committee--Japan, pp.1421-1424, 1995.

L. Weber, M. Shipkova, V. Armstrong, N. Wagner, E. Schutz et al., The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy, J Am Soc Nephrol, vol.13, pp.759-768, 2002.

L. Weber, M. Shipkova, V. Armstrong, N. Wagner, E. Schutz et al., Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy, Clin Chem, vol.48, pp.517-525, 2002.